Eli Lilly and Company
Parenteral Medicines & Device Manufacturing Facility
In 2019, Eli Lilly needed site selection and incentives consultation services for the company’s site search for a new $470 million manufacturing facility to produce parenteral (injectable) medicines and delivery systems. The state-of-the-art facility will employ over 460 employees ranging from scientists and engineers to QC staff and operators. The highly competitive search which also considered sites in the Indianapolis and Philadelphia metros selected a greenfield site in Durham, North Carolina for the new facility in January 2020. As part of the search, incentive benefits estimated at approximately $12 million from participating state & local governments and utility providers.